The FDA received Merck's new drug application for a tablet form of antifungal posaconazole, or Nozafil. The liquid formulation of the drug is already available to treat "severely immunocompromised" patients at high risk of developing Aspergillus and Candida infections.
Merck submits tablet form of Nozafil for FDA approval
SmartBrief Job Listings for Health Care
|Account Management and Product Development Specialist||
Sharp Health Plan
|San Diego, CA|
|Chief Operating Officer||
Presence Health Partners
|Des Plaines, IL|
|Sr. Business Systems Analyst||
|Sr. Reimbursement Analyst||
Olympus America Inc.